Abbott India Q2 FY26 Results: 7.6% Sales Growth, 15.8% Profit Surge — Pharma’s Most Stable Drama Continues
1. At a Glance
Abbott India Ltd, the ₹62,578 crore pharma aristocrat, just dropped its Q2 FY26 numbers — and they’re as smooth as its branded vitamins. Revenue came in at ₹1,757 crore (up 7.6% YoY) while net profit jumped 15.8% YoY to ₹415 crore. With an OPM of 29% and an ROE of 35.7%, Abbott is basically the “Shah Rukh Khan” of pharmaceuticals — aging like fine collagen.
Despite the stock sulking 10.3% over the last three months, Abbott continues to command a P/E of 41.5x — because who doesn’t love a predictable dividend-paying MNC? It’s debt-light (₹182 crore), sitting on ₹5,694 crore worth of assets, and still delivering a 17.5% annual profit growth. Yet, the company’s 15.6x price-to-book screams, “premium hai boss.”
From Brufen gels to Vitamin D gummies, Abbott’s shelves are full, its margins are fat, and its boardroom… mildly dramatic. With frequent CFO exits and MD musical chairs, it’s like watching a corporate soap opera — only with better cash flow.
2. Introduction
Abbott India isn’t here to play the quarter-to-quarter hustle game — it’s here to dominate your medicine cabinet. Established in 1944 (back when paracetamol was cool), the company today stands as the suave, well-dressed face of Indian pharmaceuticals.
With seven brands in the Indian Pharmaceutical Market’s (IPM) Top 100, Abbott has achieved what every Indian parent dreams of — consistency. While local rivals experiment with new-age drugs and risky biosimilars, Abbott is chilling with its Brufen, Thyrowel, and Arachitol army — minting profits from your daily aches, acids, and anxieties.
In FY24, it launched eight new products and followed up in November 2024 with PneumoShield 14 — a 14-valent vaccine protecting children against pneumococcal bacterial infections. This was a power move, turning pediatric defense into a profit center.
But behind the polished numbers is a slightly spicy year. Between FY24 and FY25, the firm went through a CFO carousel, MD resignations, and plant director exits faster than interns change Excel sheets. Still, the Goa plant hums along, churning 14% of sales, while contract manufacturers fill the rest.
Abbott India doesn’t shout innovation — it whispers reliability. And in the pharma world, that’s worth its weight in APIs.
3. Business Model – WTF Do They Even Do?
Let’s simplify: Abbott India sells branded generic medicines — the doctor-approved, trust-loaded kind. It focuses on lifestyle and chronic therapies — gastro, women’s health, CNS (central nervous system), metabolic, and multi-specialty.
It’s the company behind household legends: Thyronorm (thyroid care), Brufen (pain relief), Arachitol (Vitamin D), and Duphaston (women’s health). Essentially, it’s your friendly neighborhood drug dealer, only with an FDA license.
About 98% of its revenue comes from India — yes, the same country where we pop Brufen for everything from back pain to heartbreak. The remaining ~2% trickles in from exports to Sri Lanka, Nepal, Maldives, and Bhutan — tiny but loyal customers.
Manufacturing happens at its Goa plant (producing 14% of net sales) and through third-party contracts across India. Abbott’s distribution network — 3,250 sales reps strong — ensures even your local chemist in Jalgaon or Jalna has its tablets.
It’s a pharma MNC’s dream setup: one big Indian factory, a web of distributors, and a marketing army that could sell multivitamins as life insurance.
4. Financials Overview
Metric (₹ Cr)
Sep 2025 (Latest)
Sep 2024 (YoY)
Jun 2025 (QoQ)
YoY %
QoQ %
Revenue
1,757
1,633
1,738
7.6%
1.1%
EBITDA
502
439
446
14.3%
12.6%
PAT
415
359
366
15.8%
13.4%
EPS (₹)
195.4
168.8
172.2
15.8%
13.5%
Abbott’s quarterly numbers are a masterclass in “no surprises.” Sales up modestly, profits up nicely, and margins fat at 29%. It’s the corporate equivalent of an A+ student who still brings ladoos to class.
Annualized EPS = ₹195.4 × 4 = ₹781.6 → which means at ₹29,455 per share, P/E = ~37.7x. Expensive? Sure. But then again, you’re paying for a stress-free pharma story — not a biotech gamble.
